A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

Whether you have a diagnosis or are curious about your options, this guide answers some of the most common questions about injectable medications for type 2 diabetes. Injectable medications ...

Rosuvastatin comes as an oral tablet and belongs to a group of drugs called statins. Rosuvastatin is available as the brand-name drug Crestor. It’s also available as a generic drug. Generic ...

Xadago is a brand-name oral tablet that’s prescribed for Parkinson’s disease. If you have problems with side effects from Xadago, talk with your doctor or pharmacist. They can discuss ways to ...

Angiotensin-converting enzyme (ACE) inhibitors are oral medications that lower blood pressure ... uterine fibroids, and more. With diabetes, ACE inhibitors don’t directly lower blood sugar, but they ...

Other factors, including your specific diagnosis, body weight, and medical history, may affect your dosage of ciprofloxacin. Ciprofloxacin is a generic drug that comes as an oral tablet.

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

American pharmaceutical company Eli Lilly and Company this week announced results from a late-stage clinical trial for its oral diabetes medicine, orforglipron. The once-daily pill, currently ...

An experimental pill may work just as well as injectable, Ozempic-style drugs at treating type 2 diabetes, early trial results suggest. GLP-1 agonists are best known as weight-loss drugs ...

its once-daily oral GLP-1 drug for type 2 diabetes. Warning! GuruFocus has detected 6 Warning Sign with UNH. In its ACHIEVE-1 trial, the drug met its primary goal of reducing A1Ca key diabetes ...

Eli Lilly (NYSE:LLY) shares surged around 14% in premarket trading Thursday after the company reported positive Phase 3 trial results for orforglipron, its once-daily oral GLP-1 drug for type 2 ...